DrugPatentWatch Database Preview

RITUXAN Drug Profile

Email this page to a colleague

« Back to Dashboard

Summary for Tradename: RITUXAN

Patents:	848
Applicants:	2
BLAs:	2
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for RITUXAN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RITUXAN

Recent Clinical Trials for RITUXAN

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Incyte Corporation	Phase 3
AbbVie	Phase 1
Oregon Health and Science University	Phase 1

See all RITUXAN clinical trials

Recent Litigation for RITUXAN

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
Ravgen, Inc. v. Progenity, Inc.	2020-12-20
Ravgen, Inc. v. Myriad Genetics, Inc.	2020-12-20
Ravgen, Inc. v. Illumina, Inc.	2020-12-02

See all RITUXAN litigation

PTAB Litigation

Petitioner	Date
Celltrion, Inc.	2018-05-04
Apotex Inc.	2018-02-23
Forty Seven, Inc.	2018-01-08

See all RITUXAN litigation

Pharmacology for RITUXAN

Mechanism of Action

CD20-directed Antibody Interactions

Patent Text Search: US Patents for RITUXAN

These patents were identified by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Genentech	RITUXAN	rituximab	SOLUTION;INTRAVENOUS	103705	001	1997-11-26		SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (Seoul, KR)	2032-09-12	RX		search
Genentech	RITUXAN	rituximab	SOLUTION;INTRAVENOUS	103705	001	1997-11-26		Pharmacyclics LLC (Sunnyvale, CA)	2030-06-03	RX		search
Genentech	RITUXAN	rituximab	SOLUTION;INTRAVENOUS	103705	001	1997-11-26		Array BioPharma Inc. (Boulder, CO)	2028-10-22	RX		search
Genentech	RITUXAN	rituximab	SOLUTION;INTRAVENOUS	103705	001	1997-11-26		SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL)	2033-03-11	RX		search
Genentech	RITUXAN	rituximab	SOLUTION;INTRAVENOUS	103705	001	1997-11-26		YALE UNIVERSITY (New Haven, CT)	2021-05-01	RX		search
Genentech	RITUXAN	rituximab	SOLUTION;INTRAVENOUS	103705	001	1997-11-26		VentiRx Pharmaceuticals, Inc. (Seattle, WA)	2030-04-21	RX		search

International Patents for RITUXAN

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2012032433
Mexico	2007014497
Australia	2019213337
European Patent Office	2272513
China	108137585
Singapore	181533

Supplementary Protection Certificates for RITUXAN

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
132016000119245	Italy		PRODUCT NAME: IBRUTINIB O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE PER IL TRATTAMENTO DI PAZIENTI ADULTI CON LEUCEMIA LINFOCITICA CRONICA (CLL) PRECEDENTEMENTE NON TRATTATA(IMBRUVICA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/945, 20160530
LUC00044	Luxembourg		PRODUCT NAME: INOTUZUMAB OZOGAMICINE ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (BESPONSA ); AUTHORISATION NUMBER AND DATE: EU/1/17/1200 20170703
18/2015	Austria		PRODUCT NAME: IBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ; REGISTRATION NO/DATE: EU/1/14/945 20141021
212 50002-2015	Slovakia		PRODUCT NAME: POMALIDOMID; REGISTRATION NO/DATE: EU/1/13/850/001 - EU/1/13/850/004 20130808
1790062-2	Sweden		PRODUCT NAME: SARILUMAB; REG. NO/DATE: EU/1/17/1196 20170627
5/2015	Austria		PRODUCT NAME: POMALIDOMID UND SEINE PHARMAZEUTISCH AKZEPTABLEN SALZE, SOLVATE, HYDRATE ODER STEREOISOMERE; REGISTRATION NO/DATE: EU/1/13/850 20130805